What is Driving the Growth of the Preeclampsia Market?

The preeclampsia market is expanding globally due to rising awareness of maternal health, increasing prevalence of high-risk pregnancies, and ongoing advancements in treatment pipelines. In 2024, the market was valued at USD 724.30 million and is anticipated to grow at a CAGR of 8.10%, reaching USD 1,578.25 million by 2034.

Preeclampsia is a pregnancy-related disorder characterized by high blood pressure and damage to organ systems, most commonly the liver and kidneys. If untreated, it can progress to severe complications for both the mother and the baby, including eclampsia, preterm delivery, and long-term cardiovascular risks. As a leading cause of maternal and neonatal morbidity, the disorder is a global healthcare priority, driving investments in diagnostics, preventive therapies, and effective treatment regimens.

Preeclampsia Market Overview

Preeclampsia develops typically after the 20th week of pregnancy and affects about 2–8% of pregnancies worldwide. The disorder is classified as either mild or severe preeclampsia, depending on the extent of clinical symptoms.

Key Factors Contributing to Market Expansion:

• Increasing maternal age and higher rates of obesity, diabetes, and hypertension.

• Growth in maternal healthcare programs across developed and developing regions.

• Advances in early diagnosis and biomarker screening tools.

• Rising R&D efforts for novel therapeutics and preventive interventions.

• Expanding distribution channels (hospital, retail, and online pharmacies).

Preeclampsia Market by Type

• Mild Preeclampsia:

  • Managed with regular monitoring, antihypertensives, and lifestyle interventions.

  • More prevalent type, driving baseline demand for drugs and diagnostics.

• Severe Preeclampsia:

  • Requires immediate intervention, often hospitalization and specialized care.

  • Major contributor to potential long-term market opportunities due to complex therapy requirements.

Preeclampsia Market by Treatment

• Antihypertensives:

  • First-line therapy to control blood pressure in pregnant women.

  • Examples include labetalol, nifedipine, and methyldopa.

• Corticosteroids:

  • Given to promote fetal lung maturity in cases of preterm delivery due to preeclampsia.

• Anticonvulsant Medications:

  • Critical for preventing seizures, especially in severe preeclampsia and eclampsia.

  • Magnesium sulfate is the most widely used agent.

Preeclampsia Market by Route of Administration

• Oral:

  • Most common route for antihypertensive drugs prescribed during pregnancy.

• Parenteral:

  • Includes intravenous magnesium sulfate and other injectable agents used in severe cases.

• Others:

  • Includes investigational therapies currently in development.

Preeclampsia Market by End User

• Hospitals:

  • Major segment, as most severe cases require inpatient diagnosis and treatment.

• Specialty Clinics:

  • Provide ongoing monitoring and preventive care for high-risk pregnancies.

• Diagnostic Centers:

  • Increasing role in biomarker screening and early detection.

• Others:

  • Includes academic and research institutes focusing on maternal health innovation.

Preeclampsia Market by Distribution Channel

• Hospital Pharmacies:

  • Main distribution channel for prescription drugs and injectables used in inpatient care.

• Retail Pharmacies:

  • Widely cater to antihypertensive medications for mild preeclampsia.

• Online Pharmacies:

  • Fastest-growing channel due to convenience and rising telemedicine usage for maternal healthcare.

Preeclampsia Market by Region

• United States:

  • Largest market due to high maternal health expenditure and robust healthcare infrastructure.

• United Kingdom & EU-4 (Germany, France, Italy, Spain):

  • Expansion driven by structured maternal health programs and early adoption of diagnostics.

• Japan:

  • Advanced healthcare systems supporting maternal-fetal medicine innovations.

• India:

  • Rising birth rates and growing burden of hypertension in pregnancy make it a high-potential growth market.

Competitive Landscape: Key Companies

The preeclampsia market is moderately fragmented, with both global pharma leaders and regional companies investing in new therapies.

Major players include:

• Pfizer Inc. – Extensive portfolio in antihypertensives and women’s health.

• Novartis AG – Active in hypertension therapies.

• Merck & Co., Inc. – Offers corticosteroids and maternal health-focused research initiatives.

• Johnson & Johnson Innovative Medicine – Maternal health pipeline developments.

• Sanofi – Expanding treatments for high-risk pregnancy-related complications.

• Boehringer Ingelheim – Innovating cardiovascular solutions applied to maternal health.

• AstraZeneca plc – Active in cardiovascular drug development with applications in pregnancy.

• Daiichi Sankyo – Hypertension-focused therapeutics pipeline.

• Lupin – Strong presence in generics for antihypertensive medications.

• Teva Pharmaceutical Industries Ltd. – Broad portfolio covering critical maternal drugs.

Future Outlook of the Preeclampsia Market

The global preeclampsia market is set for strong growth, underpinned by an increasing focus on early interventions, novel therapeutics, and digital health tools.

Key Trends to Watch:

• Biomarker-driven diagnostics for early prediction of preeclampsia.

• Development of disease-modifying therapies beyond blood pressure management.

• Telehealth adoption for continuous monitoring of high-risk pregnancies.

• Investment in AI-based monitoring to detect early symptoms and improve clinical decisions.

• Expansion of maternal health public-private partnerships in emerging economies.

By 2034, treatment approaches are expected to evolve from primarily supportive therapies to innovative preventive and disease-modifying options, reducing maternal and neonatal mortality significantly.

Access More Reports

Advanced Wound Care Market

Artificial Insemination Market

Amyotrophic Lateral Sclerosis Market

Dementia Drugs Market

About Us:

Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.

Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.

Media Contact:

Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: [email protected]
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com